Stock AnalizMarsh & Mclennan Companies, Inc. MRSH
Specialty Insurers · data as of November 13, 2026
Marsh & Mclennan Companies, Inc. (MRSH) is a financial company listed in the US with a market value of about $98.8B. In the twelve months to September 30, 2026 it had revenue of $28.5B and net income of $4.0B, a net margin of 14.2%.
Its overall Stock Analiz score is 3.0 out of 5 (average). The strongest part is track record (5/5); the weakest is value (1/5).
Key numbers: a P/E of 24.9, a price to free cash flow of 23.8, 5-year revenue growth of 9% a year, a 5-year average ROIC of 13%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 44% below the current price.
Score: 3.0 / 5
Checks passed
- P/E below 25
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- ROE above 15%
Checks not passed
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $28.5B | $27.0B | $24.5B | $22.7B | $20.7B | $19.8B | $17.2B | $16.7B | $14.9B | $14.0B | $13.2B |
| Net income | $4.0B | $4.2B | $4.1B | $3.8B | $3.0B | $3.1B | $2.0B | $1.7B | $1.6B | $1.5B | $1.8B |
| Free cash flow | $4.2B | $5.0B | $4.0B | $3.8B | $3.0B | $3.1B | $3.0B | $1.9B | $2.1B | $1.6B | $1.8B |
| EPS (diluted) | $8.36 | $8.43 | $8.18 | $7.53 | $6.04 | $6.13 | $3.94 | $3.41 | $3.23 | $2.87 | $3.38 |
| Net margin | 14.2% | 15.4% | 16.6% | 16.5% | 14.7% | 15.9% | 11.7% | 10.5% | 11.0% | 10.6% | 13.4% |
| ROIC | — | 12.9% | 12.3% | 14.4% | 13.4% | 13.3% | 9.8% | 8.8% | 15.3% | 11.7% | 16.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 21 analysts is $206.62, 1% below the current price; targets range from $180.00 to $230.00; the consensus rating is “Buy”; expected EPS is $10.49 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Marsh & Mclennan Companies’s P/E ratio?
About 24.9, based on the last twelve months of diluted earnings per share (forward P/E about 18.0).
Is Marsh & Mclennan Companies stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 44% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Marsh & Mclennan Companies pay a dividend?
Yes. The dividend yield is about 1.91%, and it has paid dividends for 10 years in our data.
Is Marsh & Mclennan Companies a good stock to buy?
We do not give buy or sell advice. Marsh & Mclennan Companies scores 3.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.